Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
The incidence of early-onset colorectal cancer (CRC), defined as CRC occurring in individuals younger than 50 years, is increasing globally. Emerging evidence suggests that the incidence and prevalence of CRC in individuals aged 45-49 years approach those in individuals aged 50-59 years. To address this concerning trend, many health care systems and clinical specialist societies are advocating for lowering the age of initiation for CRC screening in individuals at average risk to 45 years. The present review, provided by the Canadian Association of General Surgeons Clinical Practice Committee, gives an overview of the current CRC screening guidelines in Canada, the rationale for earlier screening, and the challenges and impact of lowering the screening age to 45 years to health care systems in Canada.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12342832 | PMC |
| http://dx.doi.org/10.1503/cjs.000825 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Cuticular hydrocarbons as pupal age markers of two species of blowflies Chrysomya (Diptera: Calliphoridae): Implications for estimating the postmortem interval.
J Forensic Sci
September 2025
Laboratório de Ecologia Comportamental, Universidade Estadual de Mato Grosso do Sul (UEMS), Dourados, Mato Grosso do Sul, Brazil.
Blowflies are important to estimate the postmortem interval (PMI), since they are the first to interact with the carcass. However, depending on the decomposition stage, only pupae can be found. A method that has currently been suggested is the use of cuticular hydrocarbons (CHCs) in forensically important fly species to aid in estimating PMI; however, studies from the pupal stage are rare.
View Article and Find Full Text PDFTirzepatide for the Maintenance of Body Weight Reduction: Rationale, Design, and Baseline Characteristics of SURMOUNT-MAINTAIN.
Obesity (Silver Spring)
September 2025
Eli Lilly and Company, Indianapolis, Indiana, USA.
Objective: SURMOUNT-MAINTAIN aims to evaluate the efficacy and safety of reducing the tirzepatide dose and/or continuing the maximum tolerated dose (MTD) versus placebo in maintaining body weight (BW) reduction achieved with tirzepatide MTD.
Methods: This Phase 3b, multicenter, randomized, parallel-arm, double-blinded, placebo-controlled, 52-week clinical trial is in progress comparing treatment with once weekly tirzepatide (5 mg and/or MTD of 15 mg or 10 mg) versus placebo in achieving BW reduction maintenance from the initial 60-week open-label weight-loss period on tirzepatide MTD, in adults with obesity (BMI ≥ 30 kg/m or ≥ 27 kg/m with ≥ 1 obesity-related comorbidity, excluding type 2 diabetes). The primary endpoint is percent maintenance of BW reduction achieved during the weight-loss period at Week 112 among those who reached a BW plateau (i.
Initiation of tocilizumab within 24 hours in acute necrotizing encephalopathy is related to a good outcome: a systematic review.
J Neurol
September 2025
Department of Neurology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China.
Objective: To evaluate the clinical efficacy of tocilizumab, a interleukin-6 (IL-6) receptor blocker, for the treatment of acute necrotizing encephalopathy (ANE).
Methods: PubMed, Cochrane Library, Embase, and Web of Science were searched for systematic review based on PRISMA guidelines. ANE patients treated with and without tocilizumab were included.
Routine cell-free DNA prenatal screening identifies pregnancies at high risk for cystic fibrosis that may benefit from fetal therapy.
J Cyst Fibros
September 2025
Department of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine, Oregon Health and Science University, Portland, OR, USA.
Recent improvements in cell-free DNA technology have enabled non-invasive prenatal testing (NIPT) to screen for fetal single-gene autosomal recessive conditions from maternal blood as early as the first trimester. This technique can determine the fetal risk for cystic fibrosis (CF) with a single blood sample from a pregnant person without the need for a partner sample, which is required for traditional carrier screening. A retrospective review of 100,106 consecutive general-risk pregnant patients who underwent CF carrier screening was completed.
View Article and Find Full Text PDFNon-Sedated Intrauterine Device Experiences Among Transgender and Cisgender Adolescents and Young Adults in the Outpatient Setting.
J Pediatr Adolesc Gynecol
September 2025
Division of Adolescent Medicine, Seattle Children's Hospital, Seattle, WA, USA.
Study Objectives: This study compares the demographic characteristics and experiences of three different groups of adolescent and young adults (AYAs) seeking non-sedated intrauterine device (IUD) insertion in the outpatient setting: (1) cisgender individuals, (2) transgender and gender diverse (TGD) individuals receiving gender-affirming testosterone therapy, and (3) TGD individuals not receiving gender-affirming testosterone therapy.
Methods: This retrospective cohort study included AYAs age 13 to 21 years seeking IUD insertion. Data were obtained from the electronic health record via a pre-existing, multi-institutional shared quality improvement (QI) collaborative.